Showing results (201-210 of 227) with videos related to

Sort By:
Pageof 23
British Journal of Clinical Pharmacology|November 1, 1993
Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulationW N Charman, S A Charman, D C Monkhouse, et al.
The Journal of Clinical Investigation|October 23, 1997
Localization of distinct F2-isoprostanes in human atherosclerotic lesionsD Praticò, L Iuliano, A Mauriello, et al.
The American Review of Respiratory Disease|January 1, 1989
Allergen-stimulated release of mediators into sheep bronchoalveolar lavage fluid. Effect of cyclooxygenase inhibitionR Dworski, J R Sheller, N E Wickersham, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 22, 2011
Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticusG E Serrano, N Lelutiu, A Rojas, et al.
Circulation|February 18, 1997
Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets that had undergone anoxia and then reoxygenatedR Leo, D Praticò, L Iuliano, et al.
Blood|May 9, 2001
Effect of the Pl(A2) alloantigen on the function of beta(3)-integrins in plateletsJ S Bennett, F Catella-Lawson, A R Rut, et al.
Circulation|December 22, 1998
Increased formation of distinct F2 isoprostanes in hypercholesterolemiaM P Reilly, D Praticò, N Delanty, et al.
Circulation|June 22, 2000
Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivoL P Audoly, B Rocca, J E Fabre, et al.
The New England Journal of Medicine|December 26, 2001
Cyclooxygenase inhibitors and the antiplatelet effects of aspirinF Catella-Lawson, M P Reilly, S C Kapoor, et al.
The Journal of Biological Chemistry|October 12, 2000
Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein ER K Tangirala, D Praticó, G A FitzGerald, et al.
Pageof 23